LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Akciju saraksts・Myriad Genetics Inc

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

4.53 4.14

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.31

Max

4.53

Galvenie mērījumi
By Trading Economics
Ienākumi	-26M -34M
Pārdošana	-9.4M 200M
EPS	-0.09
Peļņas marža	-17.016
Darbinieki	2,700
EBITDA	43M -18M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+70.84% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-52M 415M
Iepriekšējā atvēršanas cena	0.39
Iepriekšējā slēgšanas cena	4.53

Ziņu noskaņojums

By Acuity

23%

77%

47 / 344 Rangs Healthcare

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. jūn. 23:49 UTC

Tirgus saruna

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

2026. g. 9. jūn. 23:45 UTC

Iegādes, apvienošanās, pārņemšana

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

2026. g. 9. jūn. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

2026. g. 9. jūn. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

2026. g. 9. jūn. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

2026. g. 9. jūn. 23:35 UTC

Tirgus saruna

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

2026. g. 9. jūn. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Additional Investment Makes It Largest Shareholder in Element

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

2026. g. 9. jūn. 20:51 UTC

Peļņas

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 9. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. jūn. 20:09 UTC

Tirgus saruna

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

2026. g. 9. jūn. 19:36 UTC

Tirgus saruna

Cattle Climbs as Crude Oil Falls -- Market Talk

2026. g. 9. jūn. 19:32 UTC

Tirgus saruna

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

2026. g. 9. jūn. 19:25 UTC

Tirgus saruna

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

2026. g. 9. jūn. 19:00 UTC

Tirgus saruna

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

2026. g. 9. jūn. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

2026. g. 9. jūn. 18:47 UTC

Tirgus saruna

No World Cup Inflation Seen So Far in Mexico -- Market Talk

2026. g. 9. jūn. 18:37 UTC

Tirgus saruna

Canada's Cooling Trade With the U.S. -- Market Talk

2026. g. 9. jūn. 18:27 UTC

Tirgus saruna

Precious Metals Lower as Trump Vows Military Response -- Market Talk

2026. g. 9. jūn. 17:35 UTC

Tirgus saruna

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

2026. g. 9. jūn. 17:30 UTC

Tirgus saruna

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

2026. g. 9. jūn. 16:34 UTC

Tirgus saruna

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2026. g. 9. jūn. 15:28 UTC

Tirgus saruna

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

2026. g. 9. jūn. 15:25 UTC

Tirgus saruna

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

70.84% augšup

Prognoze 12 mēnešiem

Vidējais 7.5 USD 70.84%

Augstākais 10 USD

Zemākais 5.5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

47 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.